Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AUNG NAING

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1104837590
CMS profile
366226
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,639.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Incyte Corporation $2,639.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AUNG NAING

NPI 1104837590 · CMS profile ID 366226

Allopathic & Osteopathic Physicians / Internal Medicine

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
AUNG NAING, NPI 1104837590, CMS profile ID 366226, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1104837590?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $2,639.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $2,639.0004/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835545359 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,309.43 16
PY2020 $211.34 1
PY2021 $2,639.00 1
PY2022 $5,205.00 2
PY2023 $3,375.00 2
PY2025 $4,703.88 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,918,481.53 469
PY2024 Recipient $4,531.10 4
PY2024 Principal investigator $4,445,667.71 159
PY2023 Principal investigator $4,761,955.67 97
PY2022 Principal investigator $3,708,621.77 334
PY2021 Principal investigator $5,802,399.26 154
PY2020 Recipient $2,459.66 4
PY2020 Principal investigator $1,927,221.68 148
PY2019 Principal investigator $5,972,979.75 356

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

163 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $12,055.67 12/31/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label Phase 1b,2a Study of NT-I7 Hyleukin-7 in Combination with Pembrolizumab in Subjects with Relapsed,Refractory Advanced Solid Tumors No dispute reported 06/30/2026 1136444246
Principal investigator 1 Servier BioInnovation $52,212.21 12/20/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016913
Principal investigator 1 Servier BioInnovation $1,187.50 12/20/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016915
Principal investigator 1 Servier BioInnovation $875.00 12/20/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016917
Principal investigator 1 Servier BioInnovation $312.50 12/20/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016919
Principal investigator 1 Servier BioInnovation $4,062.50 12/20/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016921
Principal investigator 1 Servier BioInnovation $4,080.90 12/20/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016923
Principal investigator 1 Servier BioInnovation $1,687.50 12/20/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016925
Principal investigator 1 Servier BioInnovation $17,000.00 12/20/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016927
Principal investigator 1 Servier BioInnovation $13,281.25 12/20/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016929
Principal investigator 1 Servier BioInnovation $93.94 12/20/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016931
Principal investigator 1 Servier BioInnovation $31,706.81 12/20/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016933
Principal investigator 1 BioNTech SE $3,097.40 12/18/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667525
Principal investigator 1 Servier BioInnovation $1,009.06 12/18/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016907
Principal investigator 1 Servier BioInnovation $1,009.06 12/18/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016909
Principal investigator 1 BeiGene, Ltd. $43,618.00 12/17/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119715801
Recipient Servier BioInnovation $570.55 12/17/2024 Covered Recipient Physician S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153013903
Recipient Servier BioInnovation $570.55 12/17/2024 Covered Recipient Physician S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153013905
Principal investigator 1 BeiGene, Ltd. $52,040.00 12/11/2024 Non-covered Recipient Entity
UT MD Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119728597
Principal investigator 1 BioNTech SE $3,031.10 12/10/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667535
Principal investigator 1 BioNTech SE $7,474.05 12/03/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667531
Principal investigator 1 SANOFI US SERVICES INC. $58,674.84 12/02/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1128719673
Principal investigator 1 BioNTech SE $1,500.00 11/27/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT151-01 No dispute reported 06/30/2026 1150667483
Principal investigator 1 BeiGene, Ltd. $83,264.00 11/20/2024 Non-covered Recipient Entity
UT MD Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119728601
Principal investigator 1 BeiGene, Ltd. $29,073.00 11/19/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119715799
Principal investigator 1 BioNTech SE $2,819.45 11/19/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667533
Principal investigator 1 BioNTech SE $15,948.55 11/05/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667527
Recipient PFIZER INC. $3,200.00 10/31/2024 Covered Recipient Physician NIROGACESTAT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130912512
Principal investigator 1 Merck Sharp & Dohme LLC $63,900.00 10/29/2024 Non-covered Recipient Entity
MD Anderson
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin plus Docetaxel in Triple Negative Breast Cancer NeoPACT No dispute reported 06/30/2026 1136414625
Principal investigator 1 BeiGene, Ltd. $38,700.00 10/22/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119715797
Recipient Servier BioInnovation $190.00 10/14/2024 Covered Recipient Physician S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153013907
Principal investigator 1 Servier BioInnovation $2,981.53 10/09/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016935
Principal investigator 1 Servier BioInnovation $2,981.53 10/09/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016937
Principal investigator 1 Servier BioInnovation $1,009.06 10/09/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016941
Principal investigator 1 Servier BioInnovation $1,009.06 10/09/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016943
Principal investigator 1 Servier BioInnovation $1,009.06 10/09/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016945
Principal investigator 1 Merck Sharp & Dohme LLC $82,800.00 10/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
AN OPEN-LABEL PHASE 1,2A STUDY OF GV20-0251 MONOTHERAPY AND GV20-0251 IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED AND,OR REFRACTORY SOLID TUMOR MALIGNANCIES No dispute reported 06/30/2026 1136397042
Principal investigator 1 Incyte Corporation $5,893.20 10/07/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1134675583
Principal investigator 1 BioNTech SE $7,024.40 10/04/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667529
Principal investigator 1 SANOFI US SERVICES INC. $275,107.65 10/01/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1128719675
Principal investigator 1 SANOFI US SERVICES INC. $5,283.89 10/01/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1128719677
Principal investigator 1 BeiGene, Ltd. $38,967.00 09/24/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119715795
Principal investigator 1 BioNTech SE $31,747.04 09/19/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT151-01 No dispute reported 06/30/2026 1150667481
Principal investigator 1 AstraZeneca UK Limited $49,010.00 09/18/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I and II a,Open label,Modular,Dose Escalation and Dose Expansion Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of AZD2796 Anti LILRB2 Antibody in Adult Participants with Advanced Solid Tumors No dispute reported 06/30/2026 1110842832
Principal investigator 1 BioNTech SE $8,077.55 09/18/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667519
Principal investigator 1 BioNTech SE $11,182.60 09/10/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667515
Principal investigator 1 BioNTech SE $190,639.18 09/06/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT151-01 No dispute reported 06/30/2026 1150667479
Principal investigator 1 Coherus Biosciences Inc. $2,580.02 09/06/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272869
Principal investigator 1 Coherus Biosciences Inc. $1,966.33 09/06/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272871
Principal investigator 1 Coherus Biosciences Inc. $5,444.90 09/06/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272873
Principal investigator 1 Coherus Biosciences Inc. $5,900.38 09/06/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272875
Principal investigator 1 Coherus Biosciences Inc. $3,451.15 09/06/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/1b Study of CHS-388 (formerly known as SRF388) in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1147272877
Principal investigator 1 BioNTech SE $1,426.30 09/03/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667523
Principal investigator 1 SANOFI US SERVICES INC. $151,931.36 08/16/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1128719609
Principal investigator 1 BeiGene, Ltd. $25,488.00 08/13/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119715793
Principal investigator 1 BeiGene, Ltd. $31,224.00 08/08/2024 Non-covered Recipient Entity
UT MD Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119728577
Principal investigator 1 SANOFI US SERVICES INC. $136,669.09 07/24/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1128719607
Principal investigator 1 BioNTech SE $1,562.30 07/23/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667517
Principal investigator 1 BioNTech SE $7,494.45 07/16/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667513
Principal investigator 1 BeiGene, Ltd. $46,000.00 07/10/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119715809
Principal investigator 1 BioNTech SE $23,137.00 07/10/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667521
Principal investigator 1 Incyte Corporation $82,925.96 07/09/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1134675581
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $596.53 07/03/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I/II FIH STING Monotherapy/Combination in advanced solid tumors No dispute reported 06/30/2026 1123474263
Principal investigator 1 BeiGene, Ltd. $62,448.00 06/26/2024 Non-covered Recipient Entity
UT MD Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119728581
Principal investigator 1 BioNTech SE $1,159.40 06/25/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667503
Principal investigator 1 BeiGene, Ltd. $172,146.00 06/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119715807
Principal investigator 1 BeiGene, Ltd. $31,224.00 06/12/2024 Non-covered Recipient Entity
UT MD Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119728583
Principal investigator 1 BioNTech SE $1,134.75 06/11/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667501
Principal investigator 1 SANOFI US SERVICES INC. $27,392.96 06/10/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
New TED/TCD --- Phase 1 Oncology No dispute reported 06/30/2026 1128719477
Principal investigator 1 BeiGene, Ltd. $41,632.00 05/21/2024 Non-covered Recipient Entity
UT MD Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119728587
Principal investigator 1 BioNTech SE $3,310.75 05/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667499
Principal investigator 1 BioNTech SE $15,355.25 05/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667511
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,500.00 05/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase IIB TMB High Pan Tumor (FA for tTMB) - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) No dispute reported 06/30/2026 1123474291
Principal investigator 1 BeiGene, Ltd. $93,810.00 05/17/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119715805
Principal investigator 1 Merck Sharp & Dohme LLC $78,100.00 05/15/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-label Phase 1b,2a Study of NT-I7 Hyleukin-7 in Combination with Pembrolizumab in Subjects with Relapsed,Refractory Advanced Solid Tumors No dispute reported 06/30/2026 1136444662
Principal investigator 1 Merck Sharp & Dohme LLC $170,400.00 05/14/2024 Non-covered Recipient Entity
MD Anderson
A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1136441745
Principal investigator 1 Incyte Corporation $144,499.92 05/07/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1134675579
Principal investigator 1 BioNTech SE $2,331.55 05/01/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667505
Principal investigator 1 SANOFI US SERVICES INC. $44,517.97 05/01/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1128719489
Principal investigator 1 SANOFI US SERVICES INC. $7,091.60 05/01/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1128719491
Principal investigator 1 SANOFI US SERVICES INC. $7,091.60 05/01/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors No dispute reported 06/30/2026 1128719493
Principal investigator 1 BeiGene, Ltd. $31,224.00 04/24/2024 Non-covered Recipient Entity
UT MD Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119728593
Principal investigator 1 BioNTech SE $2,983.50 04/23/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667507
Principal investigator 1 Merck Sharp & Dohme LLC $251,658.55 04/22/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers No dispute reported 06/30/2026 1136411860
Principal investigator 1 BeiGene, Ltd. $20,322.00 04/19/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119715803
Principal investigator 1 BioNTech SE $26,336.40 04/16/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667509
Principal investigator 1 Incyte Corporation $13,932.00 04/16/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1134675585
Principal investigator 1 Incyte Corporation $266,260.58 04/16/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1134675587
Principal investigator 1 SANOFI US SERVICES INC. $525.00 04/10/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
New TED/TCD --- Phase 1 Oncology No dispute reported 06/30/2026 1128719473
Principal investigator 1 SANOFI US SERVICES INC. $424,676.02 04/10/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
New TED/TCD --- Phase 1 Oncology No dispute reported 06/30/2026 1128719475
Principal investigator 1 Servier BioInnovation $1,803.90 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017035
Principal investigator 1 Servier BioInnovation $1,355.78 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017037
Principal investigator 1 Servier BioInnovation $1,548.13 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017039
Principal investigator 1 Servier BioInnovation $3,520.14 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017041
Principal investigator 1 Servier BioInnovation $2,066.40 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017045
Principal investigator 1 Servier BioInnovation $3,697.33 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017047
Principal investigator 1 Servier BioInnovation $3,892.09 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017049
Principal investigator 1 Servier BioInnovation $2,174.84 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017051
Principal investigator 1 Servier BioInnovation $1,548.13 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017053
Principal investigator 1 Servier BioInnovation $1,443.28 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017055
Principal investigator 1 Servier BioInnovation $4,397.33 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017057
Principal investigator 1 Servier BioInnovation $3,375.33 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017059
Principal investigator 1 Servier BioInnovation $4,397.33 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017061
Principal investigator 1 Servier BioInnovation $1,355.78 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017063
Principal investigator 1 Servier BioInnovation $4,259.50 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017065
Principal investigator 1 Servier BioInnovation $2,066.40 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017067
Principal investigator 1 Servier BioInnovation $571.88 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017069
Principal investigator 1 Servier BioInnovation $3,520.14 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017071
Principal investigator 1 Servier BioInnovation $1,548.13 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017073
Principal investigator 1 Servier BioInnovation $1,355.78 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017077
Principal investigator 1 Servier BioInnovation $3,697.33 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017079
Principal investigator 1 Servier BioInnovation $4,259.50 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017083
Principal investigator 1 Servier BioInnovation $2,981.53 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017085
Principal investigator 1 Servier BioInnovation $571.88 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017091
Principal investigator 1 Servier BioInnovation $2,002.35 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017093
Principal investigator 1 Servier BioInnovation $2,174.84 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017095
Principal investigator 1 Servier BioInnovation $3,375.33 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017099
Principal investigator 1 Servier BioInnovation $3,520.14 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017101
Principal investigator 1 Servier BioInnovation $571.88 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017103
Principal investigator 1 Servier BioInnovation $3,375.33 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017105
Principal investigator 1 Servier BioInnovation $2,174.84 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017107
Principal investigator 1 Servier BioInnovation $2,002.35 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017111
Principal investigator 1 Servier BioInnovation $1,548.13 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017113
Principal investigator 1 Servier BioInnovation $1,548.13 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017119
Principal investigator 1 Servier BioInnovation $2,066.40 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017121
Principal investigator 1 Servier BioInnovation $571.88 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017123
Principal investigator 1 Servier BioInnovation $1,803.90 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017125
Principal investigator 1 Servier BioInnovation $571.88 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017131
Principal investigator 1 Servier BioInnovation $4,259.50 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017133
Principal investigator 1 Servier BioInnovation $2,002.35 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017135
Principal investigator 1 Servier BioInnovation $4,397.33 04/08/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017137
Principal investigator 1 BeiGene, Ltd. $28,778.00 03/19/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119715791
Principal investigator 1 BeiGene, Ltd. $88,270.00 03/19/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119725617
Principal investigator 1 BioNTech SE $6,920.70 03/19/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667495
Principal investigator 1 Servier BioInnovation $576.53 03/11/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017015
Principal investigator 1 BeiGene, Ltd. $18,574.00 03/04/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB 26808 Alone and in Combination with Anti PD 1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1119715789
Principal investigator 1 BioNTech SE $6,734.55 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667491
Principal investigator 1 Servier BioInnovation $2,981.53 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016981
Principal investigator 1 Servier BioInnovation $3,375.33 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016983
Principal investigator 1 Servier BioInnovation $571.88 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016985
Principal investigator 1 Servier BioInnovation $571.88 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016987
Principal investigator 1 Servier BioInnovation $3,520.14 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016989
Principal investigator 1 Servier BioInnovation $1,443.28 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016997
Principal investigator 1 Servier BioInnovation $1,803.90 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153016999
Principal investigator 1 Servier BioInnovation $3,697.33 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017001
Principal investigator 1 Servier BioInnovation $2,002.35 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017003
Principal investigator 1 Servier BioInnovation $4,259.50 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017005
Principal investigator 1 Servier BioInnovation $3,892.09 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017009
Principal investigator 1 Servier BioInnovation $1,548.13 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017017
Principal investigator 1 Servier BioInnovation $571.88 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017019
Principal investigator 1 Servier BioInnovation $4,397.33 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017023
Principal investigator 1 Servier BioInnovation $571.88 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017027
Principal investigator 1 Servier BioInnovation $1,548.13 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017029
Principal investigator 1 Servier BioInnovation $1,355.78 02/21/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations No dispute reported 06/30/2026 1153017033
Principal investigator 1 BioNTech SE $9,172.35 02/13/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667489
Principal investigator 1 Merck Sharp & Dohme LLC $7,100.00 02/13/2024 Non-covered Recipient Entity
University of Texas MD Anderson Cancer Center Laboratory Medicine
A Phase 1,2 Dose Escalation,Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies No dispute reported 06/30/2026 1136397438
Principal investigator 1 BioNTech SE $16,109.20 02/07/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667485
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,033.09 02/01/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A phase I and or II open label multi center study of the safety and efficacy of BLZ945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors No dispute reported 06/30/2026 1089693213
Principal investigator 1 BioNTech SE $128,664.50 01/31/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667497
Principal investigator 1 BioNTech SE $289.85 01/23/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667493
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6.00 01/16/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I/II FIH STING Monotherapy/Combination in advanced solid tumors No dispute reported 06/30/2026 1123474261
Principal investigator 1 BioNTech SE $289.85 01/05/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
BNT152-01C No dispute reported 06/30/2026 1150667487
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $264,363.72 01/05/2024 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase I/IIA DGK FIH Mono / Combo in Solid Tumors - CA099-003 - A Phase I/II Study of BMS-986408 Alone and In Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors No dispute reported 06/30/2026 1123474271